NervGen Pharma Corp.
NGEN:NASDAQ
NervGen is a publicly traded biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage.
Streetwise Company Fact Sheet2026/10/16 16:27:57
(NGEN:NASDAQ)
Analyst coverage
| Raymond James — Michael Freeman |
| Leerink Partners LLC — Marc Goodman |
| Stifel — Justin Keywood |
| Paradigm Capital — Scott McAuley |
| Maxim Group — Michael Okunewitch |
| Lucid Capital Markets — Elemer Piros |
| H.C. Wainwright & Co. — Raghuram Selvaraju |
| TD Cowen — Joseph Thome |
| Research Capital Corporation — Dr. Andre Uddin |
Newsletter coverage
| — |
Streetwise Reports Articles
| 10/16/2026 - View Article |
| 05/28/2026 - View Article |
| 04/28/2026 - View Article |
| 12/16/2025 - View Article |
Streetwise - NervGen Pharma Corp. Ownership Overview*
NervGen Pharma Corp. (NGEN:NASDAQ)
Restructures
No Restructures for This Company
*Share Structure as of 10/16/2026
© 2026 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
